We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ipsen Withdraws Application for Drug for Ultra-Rare Bone Disease
Ipsen Withdraws Application for Drug for Ultra-Rare Bone Disease
Ipsen has withdrawn its new drug application (NDA) for palovarotene, an experimental treatment for an ultra-rare genetic disorder that causes tendons and ligaments to be replaced by bone.